Adrenogenital Syndrome
Abnormal SEX DIFFERENTIATION or congenital DISORDERS OF SEX DEVELOPMENT caused by abnormal levels of steroid hormones expressed by the GONADS or the ADRENAL GLANDS, such as in CONGENITAL ADRENAL HYPERPLASIA and ADRENAL CORTEX NEOPLASMS. Due to abnormal steroid biosynthesis, clinical features include VIRILISM in females; FEMINIZATION in males; or precocious sexual development in children.
Subtype terms (2)
More specific conditions that are subtypes of Adrenogenital Syndrome in the MeSH hierarchy.
- Adrenal Hyperplasia, Congenital
24 drugs (15 approved, 9 experimental)
- Hyperandrogenism
26 drugs (19 approved, 7 experimental)
Drugs by status
Approved for this indication (1)
Phase 2 trials (1)
Organizations
Organization Involved with Phase 4 Indications (2)
Organization Involved with Phase 3 Indications (3)
Organization Involved with Phase 2 Indications (12)
- Millendo Therapeutics, Inc.
- National Center for Research Resources (NCRR)
- Harvard University
- University of Michigan
- University of Bergen
- University of California, San Diego
- Feinstein Institute for Medical Research
- University of Minnesota
- Helse Bergen
- Spruce Biosciences
- Children's Hospital Los Angeles
- The University of Texas, Dallas
Organization Involved with Phase 1 Indications (3)
Organization Involved with Other Experimental Indications (2)